Background {#Sec1}
==========

Epilepsy is one of most common pediatric neurologic disorders. The prevalence rate is estimated 12/1000 in pediatric patients. One third of them shows pharmacoresistance, and 40% of patients who are younger than 3 years are related to the epileptic encephalopathy \[[@CR1]\]. Epileptic encephalopathy (EE) refers to a heterogenous group of epileptic disorders, characterized by intractable seizure, impairment and regression of cognitive and behavioral functions \[[@CR1], [@CR2]\]. The causes of EE include structure anomalies, inborn errors of metabolism and genetic insults. The exploration of numerous genetic variants is attributed to wide-spreading applications of next-generation sequencing \[[@CR3]\], including ion channel mutations. Voltage-gated sodium channels are responsible for the initiation and propagation of action potentials. Malfunctions of sodium channels are involved in epileptic seizures \[[@CR4]\]. Here we reported a patient with infantile EE probably caused by a de novo missense mutation of *SCN8A* (c.3953A \> G, p.N1318S).

Case presentation {#Sec2}
=================

The 3-year-and-9-month old girl was born at term with uneventful maternal pregnancy, delivery and family history. Her birth weight and body length were both within normal limits. She had the first afebrile seizure at night sleep presented as generalized tonic-clonic seizure lasting for 1--2 min while she held the normal developemtal milestone of social smiling at her age of 2 months. Topiramate was prescribed, but seizures still happened, until oxcarbazepine monotherapy employed that seizure temporarily resolved for half a year. Later, afebrile seizure flared up and the frequency was around 1--2 fits per month, even several convulsive status epilepticus. She came to our attention 1 year later. Physical and neurologic examinations, including the head circumference, muscle tone and deep tendon reflex, and the laboratory data were all unremarkable. Metabolic survey of amino and organic acids, brain magnetic resonance imaging (MRI) and fluorodeoxyglucose (FDG)-positron emission tomography (PET) demonstrated unremarkable findings (Fig. [1](#Fig1){ref-type="fig"}). The test of Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) showed mild cognitive impairment (full scale IQ = 66). Interictal electroencephalogram (EEG) revealed normal background activity without obvious epileptiform discharge. Ictal video EEG recorded the seimology of generalized tonic, tonic-clonic seizures, and generalized electrical decrement with superimposed fast activity at EEG ictal onset (Fig. [2](#Fig2){ref-type="fig"}). Phenytoin (5 mg/kg/day), valproic acid (20 mg/kg/day), levetiracetam, clonazepam were ever tried, but there was little benefit. Meanwhile, short-term seizures that were provoked by low-grade fever developed then. Fig. 1Brain MRI and FDG-PET of the patient. **a** Brain MRI in axial view with T1/T2-FLAIR series shows unremarkable findings. **b** FDG-PET fusion with MRI shows unremarkable focal hypometabolism Fig. 2EEG at ictal onset demonstrates generalized electrical attenuation with superimposed fast activity and muscle artifacts. (paper speed: 30 mm/sec, sensitivity: 10 μV/mm, band pass: 0.5--70 Hz, notch filter: 50 Hz)

Genetic counselling was recommended because her seizures were poorly controlled. High-throughput sequencing of exons of disease-causing genes were performed on the patient and her parents. Genomic DNA extraction and library preparation followed the standard Illumina protocols (Illumina, San Diego, USA) with minor adaptation provided by Joy Orient (Joy Orient Translational Medicine Research Center Co. Ltd., Beijing, China). Agilent Bioanalyzer 2100 (Agilent Technologies, USA) was used for quality control of DNA size distribution and enrichment. Target capturing was performed using Roche (Roche AG., Basel, Switzerland) product customized by Joy Orient, which uses 91,867 probes to capture total 7,465,978 bp of exons regions of 3372 genes that are potentially associated with 4213 known Mendelian genetic diseases. A HiSeq2500 sequencer was used to perform high-throughput sequencing. Exon-enriched DNA was sequenced by the Illumina hiseq2500 platform following the manufacturer's instructions (Illumina). Raw image files were processed by the BclToFastq (Illumina) for base calling and generating the raw data. The low-quality variations were filtered out using the quality score ≥ 20 (Q20). The sequencing reads were aligned to the NCBI human reference genome version hg19 using BWA. Samtools and Pindel were used to screen SNP and indel of the sequence. All genetic variants were screened by pathogenicity, mode of inheritance and clinical phenotypes **(**Table [1](#Tab1){ref-type="table"}**).** Table 1Workflow of filtering the pathogentic variantVariants No.NoteGATK Haplotype (Total variants from a trio targeted-exome sequencing)20,076total variants from a parent-proband trio targeted sequencing1st round of Filtering criteriavariants were excluded using a hierachy of levels of filtering criteria proband wild-type5971exclude variants only in the parants but not in the proband  intron\> 30 bp2490  AF \< 0.2 or AD\< 4 or MQ \< 351124  SSR \> =7 & AF \< 0.3 indel1178  indel\> 50 bp4After 1st round of filtering Variants No. in the proband9309a five-tier system of classification for variants (ACMG guidelines, 2015)  Benign8775  Likely benign158  Uncertain significance346  Likely pathogenic23  Pathogenic72rd round of filtering criteria Pathogenic/Likly Pathogenic/Uncertain significance & OMIM368overlap these 3 types of variants with OMIM segregation analysis20a specific variant in the target gene is observed to segregate with a phenotype or disease variants which are associated with patient's clinical phenotype1SCN8A:c.3953(exon22)A \> G, p.Asn1318Ser, AF = 70/174 = 0.4AF: allele frequencyAD: allele depthMQ: Mapping quality

Importantly, a de novo heterozygous mutation c.3953A \> G in *SCN8A* (the coverage of the variant (DP) is 174, allele frequency (AF) = 70/174 = 0.4) was identified and confirmed by Sanger Sequencing (Fig. [3](#Fig3){ref-type="fig"}a). The detailed information of this variant is as the followings: *SCN8A* (NM_014191.4), missense mutation, c.3953A \> G (exon22), p.N1318S (de novo), location: chr12, 52,180,336. This missense mutation causes an amino acid substitution of an asparagine residue with a serine residue (p.N1318S) which occurs at a highly conserved LINKER position between the S4 and S5 segments in the third transmembrane domain (DIII) of SCN8A protein (Fig. [3](#Fig3){ref-type="fig"}b and c). This mutation site is absent from ClinVar \[[@CR5]\] and HGMD Public \[[@CR6]\]. It is neither recorded in the Exome Aggregation Consortium (ExAC) \[[@CR7]\], which contains exome sequencing data from 60,706 unrelated individuals, nor in our 100 in-house controls. The substitution p.N1318S is predicted to be highly deleterious by bioinformatic tools, which predict possible impact of an amino acid substitution on the structure and function of a human protein, such as Polyphen2 \[[@CR8]\] (HumDiv score = 1; HumVar score = 0.998), SIFT \[[@CR9]\] (score = 0), Mutation Taster \[[@CR10]\] (score = 1) and a comprehensive index CADD phred score (C score = 23.2) \[[@CR11]\] (Table [2](#Tab2){ref-type="table"}). Fig. 3Characterization of *SCN8A* (c.3953A \> G) mutation. **a** Sanger sequencing confirms *SCN8A* (c.3953A \> G) mutation. **b** The down-stream altered amino acid caused by the missense mutation is in a highly-conserved area. **c** This mutation is located in the internal S4-S5 linker of the DIII of SCN8A protein Table 2Evaluation of possible impact of c.3953A \> G, p.N1318S mutation of *SCN8A* by different bioinformatic prediction toolsToolsPolyPhen2CADDSIFTMutation TasterPredictionScorePredictionScore (cutoff = 12.37)PredictionScore (cutoff = 0.05)PredictionProbabilityp.N1318SDamaging1.000Deleterious23.2Deleterious0.000Disease causing1

Since the probable causative gene mutation was found, levetiracetam was stopped, but her family reported more seizures. Accordingly, the therapeutic regimen of a sodium channel blocker, lamotrigine (5 mg/kg/day), valproic acid (24 mg/kg/day) and levetiracetam (10 mg/kg/day) were employed, then she had a second temporary seizure-resolved period of 5 months, even under high fever.

Discussion and conclusions {#FPar1}
--------------------------

SCN8A is widely expressed in the central and peripheral nerve systems during the neuronal maturation \[[@CR4], [@CR12]\]. It is mapped to chromosome 12q13, encoding neuronal voltage-gated sodium channel α 8-subunit Nav1.6, which forms a complex combined with β subunits to modulate current conductance \[[@CR4], [@CR13], [@CR14]\]. Nav1.6 consists of four transmembrane domains (DI-DIV), each containing six segments (S1-S6). Four S4 transmembrane segments are responsible for the voltage sense which contain positively charged arginine and histidine residues. There are fast and slow inactivation phases. Fast-inactivation phase is provided by internal DIII-DIV linkers to occlude the ion-conducting pores. Slow-inactivation phase is involved in a collapse of the pore, which is composed of S5-S6 segments of four domains \[[@CR4]\].

Missense mutations of *SCN8A* accounting for 1% of EE are associated with a wide-spectrum phenotype of heterogenous epilepsy, and *SCN8A* missense mutations are recently recognized to be associated with early infantile epileptic encephalopathy type 13, ref. \[[@CR15]--[@CR18]\] which displays multiple seizure types, including focal seizures, generalized seizures (tonic, myoclonic, absence) and epileptic spasms. These patients may experience stormy epilepsies \[[@CR15], [@CR17]\]. Fever rarely triggers seizures \[[@CR4], [@CR13], [@CR17]\]. Severity of psychomotor delay ranges widely after seizure onset \[[@CR15], [@CR17]\]. MRI studies are typically normal \[[@CR15]\]. There is no clear correlation between phenotypic severity and genetic mutations so far \[[@CR1], [@CR4]\]. *SCN8A* mutations lead to premature channel opening, impaired inactivation and increased persistent current. Stormy seizures are reported resulting from gain-of-function effects \[[@CR4]\]. It could explain that some patients respond well to sodium channel blockers in halting seizures \[[@CR15], [@CR17], [@CR19], [@CR20]\].

As to our patient, she was categorized as the intermediate phenotype of EE, who manifested mild psychomotor retardation and infrequent seizure episodes, though developing stormy onset of generalized tonic and tonic-clonic seizures concomitant with normal EEG background activity \[[@CR15], [@CR17], [@CR18]\]. Fever barely triggered seizures in our patient as previously reported \[[@CR4], [@CR13], [@CR17]\]. MRI demonstrated no significant findings. She responds well to the sodium channel blockers. Targeted exome sequencing revealed a heterozygous missense mutation (c.3953A \> G, p.N1318S) in *SCN8A* which is located in the internal S4-S5 linker of the DIII. This mutation could alter the function of the down-stream protein. Since *SCN8A* (c.3953A \> G, p.N1318S) is a de novo missense mutation, it is necessary to further validate its function in the future.
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